INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intellia Therapeutics, Inc. - NTLA

NEW YORK, October 29, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of  Intellia Therapeutics, Inc. (“Intellia” or the “Company”) (NASDAQ: NTLA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Intellia and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action]

On October 27, 2025, Intellia announced that it had temporarily paused patient dosing and screening for its Phase 3 clinical trials of nex-z due to a serious liver safety event.  Specifically, Intellia halted its MAGNITUDE and MAGNITUDE-2 trials for patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN), respectively, after a patient dosed with nex-z in the MAGNITUDE trial on September 30 reported Grade 4 liver transaminases and increased total bilirubin. 

On this news, Intellia’s stock price fell $10.81 per share, or 42.23%, to close at $14.79 per share on October 27, 2025.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.